Preclinical studies using native GLP-1 or GLP-1RA have provided convincing evidence of its cardioprotective benefits, while clinical trials have shown positive effects on hypertension and dyslipidemia in patients with T2DM [3]
Higher-risk situations may include: Older age Existing sarcopenia or frailty Recent falls Difficulty rising from a chair Low baseline physical activity Very low protein or calorie intake Rapid or excessive appetite suppression Chronic kidney, liver, pulmonary, or cardiovascular disease Cancer or another catabolic illness Recent hospitalization Significant gastrointestinal adverse effects Very rapid weight loss Inability to participate in resistance exercise These factors do not automatically make GLP-1 therapy inappropriate
Take Back Your Health, Valerie Hope-Slocum Sutherland, MD Diplomate, American Board of Obesity Medicine 2015 Diplomate, American Board of Internal Medicine 2005 Founder, Rainier Medical Weight Loss and Wellness, 2015
As more patients are treated with these therapies, it is important to understand how they alter clinical presentations and risk for adverse effects
His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team
